Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site 407
Escondido, California, United States
- Site 379
Gardena, California, United States
- Site 378
Huntington Park, California, United States
- Site 406
La Jolla, California, United States
- Site 373
Los Angeles, California, United States
- Site 387
Tarzana, California, United States
- Site 375
Torrance, California, United States
- Site 444
Edgewater, Florida, United States
- Site 015
Fort Lauderdale, Florida, United States
- Site 009
Atlanta, Georgia, United States
- Site 097
Atlanta, Georgia, United States
- Site 046
Covington, Kentucky, United States
- Site 061
Metairie, Louisiana, United States
- Site 205
New Orleans, Louisiana, United States
- Site 377
New Orleans, Louisiana, United States
- Site 410
Baltimore, Maryland, United States
- Site 394
Hyattsville, Maryland, United States
- Site 067
Boston, Massachusetts, United States
- Site 074
Ann Arbor, Michigan, United States
- Site 371
Las Vegas, Nevada, United States
- Site 070
Albany, New York, United States
- Site 411
Smithtown, New York, United States
- Site 181
Chapel Hill, North Carolina, United States
- Site 059
Wilmington, North Carolina, United States
- Site 436
Cincinnati, Ohio, United States
- Site 042
Cleveland, Ohio, United States
- Site 077
Columbus, Ohio, United States
- Site 195
Columbus, Ohio, United States
- Site 435
Grants Pass, Oregon, United States
- Site 049
Portland, Oregon, United States
- Site 456
Cedar Park, Texas, United States
- Site 370
Dallas, Texas, United States
- Site 408
Lufkin, Texas, United States
- Site 054
San Antonio, Texas, United States
- Site 369
San Antonio, Texas, United States
- Site 405
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2023
- Primary completion
- 19 Nov 2024
- Completion
- 18 Dec 2024
- Last update posted
- 20 Jan 2025
- Registered enrollment
- 1,113
- Registry id
- NCT05772169
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.